Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
54 hedge funds and large institutions have $78.4M invested in Surface Oncology, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
11% more capital invested
Capital invested by funds: $70.5M → $78.4M (+$7.89M)
8% more funds holding
Funds holding: 50 → 54 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$389K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$278K |
| 4 |
OPPM
Opus Point Partners Management
New York
|
+$261K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$1.62M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.21M |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$679K |
| 4 |
Man Group
London,
United Kingdom
|
-$390K |
| 5 |
Morgan Stanley
New York
|
-$304K |
SURF Hedge Fund Activity: Q1 2019 in Review
54 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q1 2019, worth a combined $78.4M — up 11% from $70.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SURF positions and 3 closed out — a net gain of 4 holders — while 21 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.13M. The largest seller was Fidelity International, cutting an estimated $1.62M.
- 54 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q1 2019, up from 50 in Q4 2018.
- Funds reported $78.4M of Surface Oncology, Inc. Common Stock stock for Q1 2019, up 11% quarter-over-quarter.
- 7 funds opened new Surface Oncology, Inc. Common Stock positions in Q1 2019 and 3 closed out, a net change of +4 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q1 2019 was Vanguard Group, an estimated $2.13M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q1 2019 was Fidelity International, an estimated $1.62M sold.
Based on aggregated 13F filings for Q1 2019.